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Abstract
 
Currently there are few reliable cell surface markers that can clearly discriminate effector from
memory T cells. To determine if there are changes in O-glycosylation between these two cell
types, we analyzed virus-specific CD8 T cells at various time points after lymphocytic chorio-
meningitis virus infection of mice. Antigen-specific CD8 T cells were identified using major
histocompatibility complex class I tetramers, and glycosylation changes were monitored with a
monoclonal antibody (1B11) that recognizes O-glycans on mucin-type glycoproteins. We ob-
served a striking upregulation of a specific cell surface O-glycan epitope on virus-specific CD8
T cells during the effector phase of the primary cytotoxic T lymphocyte (CTL) response. This
upregulation showed a strong correlation with the acquisition of effector function and was
downregulated on memory CD8 T cells. Upon reinfection, there was again increased expres-
sion of this specific O-glycan epitope on secondary CTL effectors, followed once more by de-
creased expression on memory cells. Thus, this study identifies a new cell surface marker to dis-
tinguish between effector and memory CD8 T cells. This marker can be used to isolate pure
populations of effector CTLs and also to determine the proportion of memory CD8 T cells that
are recruited into the secondary response upon reencounter with antigen. This latter informa-
tion will be of value in optimizing immunization strategies for boosting CD8 T cell responses.
Key words: memory T cells • effector T cells • cytotoxic T lymphocytes • viral immunity • 
O-glycosylation
 
Introduction
 
T cells can be classified into three separate populations: na-
ive, effector, and memory (1). There are several cell surface
markers that distinguish naive from activated T cells, but
there are very few reliable markers that distinguish between
effector and memory T cells (2, 3). It is possible to differen-
tiate effector and memory T cells by the presence of spe-
cific effector molecules, such as perforin or cytokines (3, 4).
However, direct ex vivo staining of cytokines in effector T
cells is difficult, since cytokines are rapidly secreted from
these cells in vivo. Moreover, the fixation procedures used
for staining intracellular cytokines or perforin kills the cells,
and therefore these molecules cannot be used to isolate T
cells for subsequent functional studies. For these reasons,
cell surface markers that distinguish between memory and
effector T cells would be of more value. CD69 and CD25
have been quite useful in this regard and are widely used to
identify recently activated T cells. However, expression of
both of these molecules is very transient, especially that of
CD69, and it is possible to miss effector cells based on
CD69 and CD25 staining. Thus, it would be useful to
identify cell surface markers to reliably discriminate be-
tween effector and memory T cells.
Lymphocytic choriomeningitis virus (LCMV) infection
of mice is an excellent model to study T cell immunity,
and the use of MHC class I tetramers has allowed us to di-
rectly visualize antigen-specific CD8 T cells at various
times after LCMV infection (1, 4, 5). We have previously
shown that there are changes in the glycosylation patterns
of T cells after viral infection based on binding to peanut
agglutinin (PNA; reference 6). PNA binding differentiated
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between naive and activated T cells but failed to provide a
clear distinction between memory and effector CD8 T
cells. To further investigate potential glycosylation differ-
ences between effector and memory T cells, we chose the
1B11 antibody that recognizes core 2 O-glycans on mucin-
type glycoproteins such as CD43 (7, 8). Using MHC class I
tetramers, we examined the expression of the 1B11 epitope
on virus-specific CD8 T cells and show that memory T
cells can be distinguished from effector T cells based on al-
tered expression of cell surface O-glycans.
 
Materials and Methods
 
Mice, Virus, and Adoptive Transfers.
 
BALB/cByJ, C57BL/6J,
and P14 LCMV TCR-transgenic mice (2) were purchased from
The Jackson Laboratory. For primary LCMV responses, naive
adult mice were infected with 2 
 
3
 
 10
 
5
 
 pfu of LCMV-Armstrong
intraperitoneally. For secondary responses, LCMV immune mice
were rechallenged with 2 
 
3
 
 10
 
6
 
 pfu of LCMV-clone 13 or vary-
ing doses of LCMV-Armstrong intravenously. In experiments
analyzing LCMV-transgenic CD8 T cells, 2 
 
3
 
 10
 
6
 
 P14 spleno-
cytes were transferred intravenously into naive nonirradiated B6
recipient mice and infected intraperitoneally with 2 
 
3
 
 10
 
5
 
 pfu of
LCMV-Armstrong.
 
Surface/Tetramer Staining and Flow Cytometry.
 
Production of
MHC class I tetramers and cell surface staining/sorting was done
as previously described (4). Anti-CD8
 
a
 
–PE or PerCP, 1B11–
FITC or PE, and tetramer–APC were used. All antibodies were
purchased from PharMingen.
 
Direct Ex Vivo CTL Assay.
 
LCMV-specific CTL activity was
determined by a 6-h 
 
51
 
Cr-release assay as previously described (4).
 
Results
 
Kinetics of Effector CD8 CTL Response during Acute
LCMV Infection.
 
An example of the kinetics of direct ex
vivo virus-specific CTL activity during acute LCMV in-
fection and after rechallenge is shown in Fig. 1 A. The ob-
vious conclusion from this data is that effector CD8 T cells
are present at days 5, 8, 15, and after rechallenge but not at
day 80. However, a problem with such an analysis is that
the number of virus-specific CD8 T cells is vastly different
in each sample. Thus, it could be argued that the differ-
ences seen in the levels of killing do not necessarily repre-
sent a difference in the killing function of antigen-specific
CD8 T cells present in these samples but are a reflection of
the differences in the frequency of virus-specific CD8 T
cells. For example, the frequency of LCMV NP118-spe-
cific CD8 T cells in the day 8 spleen is 
 
z
 
1/8 (25% of sple-
nocytes are CD8, and 50% of these are NP118 specific,
i.e., 12.5% of spleen cells are virus specific), compared
with a frequency of 
 
z
 
1/100 in LCMV immune mice
(10% of spleen cells are CD8, and of these, 10% are NP118
specific, i.e., only 1% are virus specific; reference 4). This
means that in the CTL assay shown in Fig. 1 A, although
the E/T ratio based on total splenocytes is the same (200:1)
for the d8 and d80 samples, the E/T ratio based on the
number of virus-specific CD8 T cells is quite different, 25:1
for the d8 sample and 2:1 for the d80 sample. To deter-
mine if there is truly a difference in the cytolytic activity
between “effector” and “memory” CD8 T cells, we per-
formed a CTL assay in which all samples contained the
same number of antigen-specific CD8 T cells (Fig. 1 B).
This was done by determining the frequency of NP118-
specific CD8 T cells before the CTL assay by staining with
L
 
d
 
(NP118) tetramer and then appropriately diluting (i.e.,
normalizing) the samples using spleen cells from naive
BALB/c mice. As shown in Fig. 1 B, even when the num-
ber of LCMV-specific CD8 T cells was the same in all
samples, there was still a striking difference in CTL activ-
ity. The effector cells (days 5 and 8 after primary infection
and day 4 after rechallenge) exhibited high cytolytic activ-
Figure 1. Kinetics of direct ex vivo virus-specific CTL activity during
primary LCMV infection and after rechallenge. (A) Splenocytes from
LCMV-infected mice were analyzed for direct ex vivo CTL activity (D4
RC 5 day 4 after LCMV rechallenge). Data shown are for an E/T ratio
of 200:1. Lysis of noninfected target cells at the same E/T ratio was ,5%
(data not shown). The kinetics of viral clearance during acute LCMV in-
fection are indicated by the shaded graph. The virus levels in the spleen
peak between days 1 and 3 (at 107 pfu per spleen) and then drop precipi-
tously between days 5 and 8 to ,102 pfu per spleen. (B) The direct ex
vivo CTL activity at different time points after infection after normalizing
the number of antigen-specific CD8 T cells present in each sample. There
were 104 NP118-specific CD8 T cells present in each sample, giving an
E/T ratio of 1:1 based on virus-specific T cells. The data shown are rep-
resentative of three experiments.
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ity, whereas the same number of LCMV-specific memory
CD8 T cells showed a minimal amount of killing.
 
Expression of Cell Surface O-Glycans on Antigen-specific
CD8 T Cells.
 
We have previously shown that activated T
cells express increased neuraminidase activity and contain
hyposialylated O-glycans (6). Based on these observations,
we wanted to examine changes in O-glycosylation on the
surfaces of antigen-specific effector and memory CD8 T
cells as a potential marker to discriminate these two types of
cells. To analyze changes in O-glycosylation on effector
CD8 T cells, we costained day 5 and day 8 splenocytes
with the 1B11 antibody and MHC class I tetramers. As
shown in Fig. 2, A and B, almost all of the antigen-specific
CD8 T cells were 1B11
 
hi
 
 (86 and 96%, respectively). When
compared with the CD8 T cells from naive BALB/c mice,
which do not exhibit any LCMV-specific CTL activity
(Fig. 1 A) and have low levels of 1B11 binding (Fig. 2, A
and B), the effector phase CD8 T cells have a significant in-
crease in the O-glycan epitope recognized by 1B11.
After the LCMV infection is resolved, 
 
$
 
95% of the
CD8 T cells undergo cell death between days 8 and 30; the
remaining cells comprise a stable LCMV-specific memory
compartment (5, 9). Splenocytes taken from mice during
both of these phases (day 15 for the death phase and day 90
for the memory phase) were analyzed for LCMV-specific
cytolytic activity and 1B11 binding. By day 15, there was a
decrease in direct ex vivo CTL activity (Fig. 1, A and B)
and also a decrease in the percentage of antigen-specific
cells that were 1B11
 
hi
 
 (Fig. 2, A and B). As previously de-
scribed, the day 90 antigen-specific memory T cells dis-
played a low level of LCMV-specific cytotoxicity, and
when the NP118-specific memory T cells were analyzed
for 1B11 binding, very few of these cells were 1B11
 
hi
 
; in-
stead, these cells showed a pattern of staining similar to that
observed for naive CD8 T cells (Fig. 2, A and B). These
data demonstrate that cell surface O-glycan epitopes recog-
nized by 1B11 are more highly expressed on effector CD8
T cells than on memory T cells.
Since it appeared that we had identified a marker that
can be used to differentiate between effector and memory
T cells, it was important to look at 1B11 binding on sec-
Figure 2. Kinetic analysis of 1B11 binding to antigen-specific CD8 T
cells. (A) Splenocytes from LCMV-infected mice were stained with the
Ld(NP118) tetramer and anti-CD8 and the percentage of CD8 T cells
that were tetramer positive is noted. (B) Expression of cell surface O-gly-
cans was examined with the mAb 1B11. Within the histograms, the bold
line represents the 1B11 staining gated on the Ld(NP118)1 CD8 T cells at
each time point, and the thin line corresponds to the 1B11 staining on
naive BALB/c CD8 T cells. The percentage of 1B11hi cells within the
gated population is noted. (C) This panel shows the direct ex vivo CTL
activity as assessed on LCMV-infected targets.
Figure 3. The 1B11 O-glycan epitope is upregulated on antigen-spe-
cific effector T cells. (A) LCMV-specific CD8 T cells were obtained from
naive P14-transgenic mice or at days 5, 8, and 100 after adoptive transfer
and infection. Splenocytes from these various groups of mice were stained
with anti-CD8 and the Db(GP33) tetramer. The percent of CD8 T cells
that are GP33 specific is noted in the upper right quadrant. (B) 1B11
staining of the GP33-specific CD8 T cells. The percent of cells which are
1B11hi within the gated Db(GP33)1CD81 population is noted.
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ondary effector and memory cells. If we were indeed
marking effector T cells, 1B11 binding should again in-
crease on the secondary effectors and then be downregu-
lated on the secondary memory cells. To test this, LCMV
immune mice were rechallenged with virus and analyzed at
days 4 (secondary effector phase) and 44 (secondary mem-
ory phase) for 1B11 binding. At day 4 after rechallenge,
splenocytes again displayed a high level of LCMV-specific
CTL activity, and there was also a striking increase in 1B11
binding on antigen-specific secondary effector CD8 T cells
(Fig. 2, A and B). Antigen-specific memory CD8 T cells
present on day 44 after rechallenge again displayed a low
level of 1B11 binding, similar to that observed for memory
CD8 T cells generated after primary infection. Therefore,
binding of the 1B11 antibody, which primarily recognizes
core 2 O-glycans on mucin-type glycoproteins, clearly dis-
tinguishes between effector and memory T cells.
We have shown that 1B11 binding is upregulated on an-
tigen-specific CD8 T cells after LCMV infection, but due
to the small number of antigen-specific T cells present in
naive mice, it is not possible to analyze 1B11 binding on
the naive NP118-specific precursors. To insure that there
was not something intrinsically different about the LCMV-
specific precursor cells, we examined P14 TCR-transgenic
mice, which express a TCR specific for the H-2D
 
b
 
–
restricted GP33-41 epitope of LCMV (2). By adoptively
transferring 2 
 
3 
 
10
 
6
 
 P14 splenocytes into nonirradiated,
naive B6 mice and then giving the recipient mice an acute
LCMV infection, we were able to analyze naive, effector,
and memory LCMV-specific CD8-transgenic T cells for
the binding of 1B11. As shown in Fig. 3, A and B, naive
GP33-specific CD8 T cells demonstrated very low levels of
1B11 binding. Similar to the BALB/c system, the majority
of antigen-specific CD8 T cells from recipient mice at days
5 and 8 after infection were 1B11
 
hi
 
. Finally, the LCMV-
specific memory CD8 T cells again displayed low levels of
1B11 binding. These experiments confirm that the O-gly-
can epitope recognized by 1B11 was upregulated on effec-
tor T cells and downregulated on memory T cells.
 
1B11 Epitope Expression Directly Correlates with CD8 T
Cell Effector Function.
 
We have shown that the 1B11
epitope is upregulated on antigen-specific CD8 T cells dur-
ing the effector phase of the immune response; therefore,
this marker would be ideal for analyzing the recruitment of
memory T cells into the secondary response. As shown in
Fig. 4 A, when LCMV immune mice were rechallenged
with increasing doses of virus, the percentage of antigen-
specific CD8 T cells that became 1B11
 
hi
 
 also increased, in-
dicating that recruitment of memory CD8 T cells into the
recall response is dependent on the antigen load. The
higher the virus rechallenge dose, the greater the propor-
tion of memory CD8 T cells that became effector cells:
32% after reinfection with 10
 
5
 
 pfu, 60% with 3 
 
3
 
 10
 
5
 
 pfu,
and 80% with 2 
 
3
 
 10
 
6
 
 pfu. In data not shown, along with
Figure 4. Using the 1B11 an-
tibody to monitor recruitment
of memory CD8 T cells into the
secondary response (A) and to
isolate antigen-specific effector
CTLs (B). (A) LCMV immune
mice were rechallenged with
varying doses of LCMV-Arm-
strong intravenously, and re-
cruitment of the antigen-specific
CD8 T cells into the secondary
response was monitored by
1B11hi staining. The contour
plots show the Ld(NP118) tet-
ramer-positive CD8 T cells at
day 2 after reinfection with dif-
ferent doses of LCMV. The his-
tograms demonstrate the 1B11
staining on the gated popula-
tions from the panels on the left,
with the percentage of 1B11hi
and 1B11lo tetramer-positive
CD8 T cells noted. (B) LCMV
immune mice were reinfected
with 3 3 105 pfu LCMV-Arm-
strong intravenously, and 2 d
later, Ld(NP118) tetramer-posi-
tive CD8 T cells were sorted
into 1B11hi and 1B11lo popula-
tions. (C) The sorted 1B11hi and
1B11lo Ld(NP118) CD8 T cells
were then analyzed for their
LCMV-specific direct ex vivo
CTL activity. The level of kill-
ing on uninfected target cells
was ,6%.
 1245
 
Harrington et al. Brief Definitive Report
 
the increase in the frequency of 1B11
 
hi
 
 tetramer-positive
cells, there was an increase in the LCMV-specific CTL ac-
tivity, and this correlated with higher levels of intracellular
perforin within the 1B11
 
hi
 
 population.
To show a direct relationship between 1B11 expression
and effector function, we sorted 1B11
 
hi
 
 and 1B11
 
lo
 
LCMV-specific CD8 T cells and used them in a direct ex
vivo CTL assay. To obtain these two cell types from the
same pool of cells, we rechallenged LCMV immune mice
with a dose of LCMV that would recruit approximately
half of the memory CD8 T cells to become activated. As
shown in Fig. 4 B, 
 
z
 
50% of the L
 
d
 
(NP118)-specific CD8
T cells were 1B11
 
hi
 
, and 50% remained 1B11
 
lo
 
. These two
populations were sorted to give pure populations of 1B11
 
hi
 
and 1B11
 
lo
 
 L
 
d
 
(NP118)
 
1
 
 CD8 T cells (Fig. 4 B) and then
tested in a direct ex vivo CTL assay. Fig. 4 C shows that
the 1B11
 
hi
 
 tetramer-positive CD8 T cells exhibited high
levels of killing on virus-infected targets, whereas the
1B11
 
lo
 
 LCMV-specific CD8 T cells showed minimal kill-
ing. Thus, this data clearly establishes that the O-glycan
epitope defined by the 1B11 antibody can be used to dif-
ferentiate effector from memory CD8 T cells and that this
antibody, in combination with MHC class I tetramers, can
be used to obtain pure populations of antigen-specific ef-
fector CD8 CTLs.
 
Discussion
 
There are very few reliable cell surface markers that dis-
tinguish between effector and memory T cells. The lack of
such markers has made it difficult to determine whether the
“activated” T cells being examined are effector cells that
were recently stimulated with antigen or whether they are
true memory T cells. In this study, we have identified a
new cell surface marker to distinguish between effector and
memory T cells. We have shown that changes in cell sur-
face O-glycosylation can be used to discriminate between
these two cell populations and that these changes can be
easily monitored by the mAb 1B11. We found a striking
correlation between increased expression of cell surface
O-glycans on antigen-specific CD8 T cells and the acquisition
of CTL activity. Most importantly, we show that the 1B11
antibody in combination with MHC class I tetramers can
be used to sort effector CD8 T cells. This should provide a
convenient method of obtaining pure populations of anti-
gen-specific memory and effector T cells for subsequent bi-
ological and molecular analysis.
It is worth pointing out that the 1B11 epitope is likely to
be a better marker than CD69 or CD25 for distinguishing
between effector and memory CD8 T cells because the ex-
pression of CD69 and CD25 is very transient and is rapidly
downregulated once TCR stimulation wanes. In fact, the
vast majority (
 
.
 
90%) of LCMV-specific (tetramer-posi-
tive) CD8 T cells that are present at day 8 after infection
are both CD25 and CD69 negative (Murali-Krishna, K.,
and R. Ahmed, unpublished data). This is a somewhat sur-
prising finding, since it is well established from numerous
studies (5) that the day 8 LCMV-specific CD8 T cells ex-
hibit high levels of killing ex vivo (i.e., are effector CTLs).
However, as shown in this study, these day 8 virus-specific
effector CTLs are still 1B11
 
hi
 
.
The new marker we have identified can be used to de-
termine the proportion of memory CD8 T cells that are re-
cruited into the secondary response upon reencounter with
antigen. This information will be particularly useful in de-
veloping vaccination strategies for boosting CD8 T cell re-
sponses. Also, by using the 1B11 antibody and MHC class I
tetramers in combination with antibodies against the differ-
ent TCR V
 
b
 
 families, it should be possible to determine if
there is selective recruitment of antigen-specific memory
CD8 T cells depending on the type of vaccination regimen
used (10). This type of analysis may provide insight into the
mechanism by which “high”-affinity T cells are selected
during secondary immunization (11–13).
In this study, changes in O-glycosylation were detected
with the mAb 1B11, which was initially characterized as
recognizing an activation-associated isoform of CD43 (7).
The activation-associated CD43 isoform is a high-molecu-
lar-mass isoform that bears core 2 O-glycans, an oligosac-
charide structure that can be created by the action of the
core 2 GlcNAc transferase (14). Several studies have docu-
mented increased activity of core 2 GlcNAc transferase
during murine and human T cell activation in vitro and in
vivo (15). Increased expression of core 2 O-glycans has also
been described in viral infection, autoimmune disease, and
graft versus host disease. Mukasa et al. have recently de-
scribed the binding of a core 2 O-glycan–specific mAb,
1D4, to a subset of activated human CD4
 
1
 
CD45RO
 
1
 
 pe-
ripheral T cells (16). This result appears to be different from
our findings. However, it remains to be determined
whether similar or different molecules are being recognized
by the 1D4 and 1B11 antibodies. Also, it is possible that the
glycosylation patterns of CD4 and CD8 T cells are differ-
ent. In this context, it is worth noting that the S7 mAb that
recognizes the low-molecular-mass isoform of CD43 reacts
very differently with CD4 versus CD8 T cells (17). Both
naive and memory CD8 T cells show high levels of bind-
ing to S7, whereas only memory CD4 T cells bind high
levels of S7 (reference 17 and data not shown).
What are the functional consequences of these glycosyla-
tion changes on activated T cells? It is possible that these
changes allow for better extravasation and migration of ef-
fector T cells to sites of infection (1, 18). It is also possible
that the glycosylation changes may be involved in down-
regulating the T cell response (19–21). It is well established
that the majority of effector CD8 T cells undergo cell
death, and it is tempting to speculate that some of the ob-
served changes may play a role in the “death” phase of the
T cell response. Future studies will be directed toward ad-
dressing these questions. It will also be of interest to deter-
mine more precisely the nature of the glycosylation
changes. Core 2 O-glycans have been described on both
CD43 and CD45. Although 1B11 was initially character-
ized as specific for CD43, it is now known that this anti-
body can bind both CD43 and CD45, and a recent report
by Carlow et al. has shown that 1B11 recognition of CD45
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occurs only in the absence of core 2 O-glycans (8). This is
the opposite of CD43, as 1B11 only binds to CD43 when
core 2 structures are expressed on the molecule. Work is in
progress in our laboratories to identify the glycoproteins
recognized by 1B11 on effector CD8 T cells and to charac-
terize biochemically the changes in the glycosylation of
these molecules during the naive to effector to memory
transition.
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